JP6781252B2 - 多重染色法、及び染色キット - Google Patents
多重染色法、及び染色キット Download PDFInfo
- Publication number
- JP6781252B2 JP6781252B2 JP2018522496A JP2018522496A JP6781252B2 JP 6781252 B2 JP6781252 B2 JP 6781252B2 JP 2018522496 A JP2018522496 A JP 2018522496A JP 2018522496 A JP2018522496 A JP 2018522496A JP 6781252 B2 JP6781252 B2 JP 6781252B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- molecule
- protein
- staining
- recognizes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010186 staining Methods 0.000 title claims description 20
- 238000007447 staining method Methods 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims description 38
- 230000008859 change Effects 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 3
- 230000035772 mutation Effects 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 48
- 238000000034 method Methods 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 44
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 33
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 12
- 108091012583 BCL2 Proteins 0.000 description 12
- 229940125644 antibody drug Drugs 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000010827 pathological analysis Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101710204837 Envelope small membrane protein Proteins 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 5
- 208000034951 Genetic Translocation Diseases 0.000 description 5
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 5
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 5
- 101710120037 Toxin CcdB Proteins 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 201000003444 follicular lymphoma Diseases 0.000 description 5
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 4
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 4
- 101710088839 Replication initiation protein Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000012137 double-staining Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 2
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 101710173438 Late L2 mu core protein Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000001280 germinal center Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 101100125460 Arabidopsis thaliana IDH3 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000030315 diffuse gastric adenocarcinoma Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
(1)細胞を含む検体を固定化した標本において、複数の抗体を用いて検出する多重染色法であって、特定の分子の存在を検出するための抗体と前記特定の分子の変化を検出するための抗体とを用いることを特徴とする多重染色法。
(2)前記特定の分子が治療薬の標的となる細胞抗原タンパク質であって、当該治療薬の効果を判定するために用いることを特徴とする(1)記載の多重染色法。
(3)細胞を含む検体を固定化した標本において、分子の変化を検出するためのキットであって、特定の分子の存在を検出する抗体と前記特定の分子の変化を検出するための少なくとも1つ以上の抗体と、前記特定の分子の存在を検出する抗体と前記特定の分子の変化を検出するための少なくとも1つ以上の抗体とを、夫々識別可能に標識する標識を含むことを特徴とする多重染色キット。
(4)前記特定の分子が治療薬の標的になる細胞抗原タンパク質であって、当該治療薬の効果を判定するために用いることを特徴とする(3)記載の多重染色キット。
(5)前記特定の分子がPD-L1又はPD-L2であって、PD-L1又はPD-L2の存在を検出するための抗体と、PD-L1又はPD-L2のC末領域の変化に伴って認識されない抗体とを含むことを特徴とする(3)又は(4)記載の多重染色キット。
野生型の分子Aと欠失変異を有する分子A’とを同一切片上で同時に染色する方法について説明する(図1、欠失変異体)。野生型の分子Aと欠失変異体A’を発現する細胞を識別する場合には、野生型分子A、変異体分子A’、どちらの分子も確実に認識することのできる抗体aと欠失変異が生じることの多い領域を認識する抗体bを検出に用いれば良い。
染色体に転座が生じ、遺伝子の一部が他の遺伝子と転座により置き換わったことによる融合タンパク質B’を発現する場合について説明する(図1、染色体転座)。抗体cは、転座の有無に関わらず、タンパク質B、B’を認識する抗体を示す。抗体dは野生型タンパク質Bのみ検出し、転座が生じた場合には認識しない抗体を示す。
次に、野生型Cと点突然変異(図中●で示す。)を有する分子C’を区別して染色する方法について説明する(図1、点突然変異)。抗体eは野生型C、点突然変異体C’に関わらず認識する抗体を示す。抗体fは野生型Cのみを認識し、点突然変異体C’は認識しない抗体を示す。
次に、修飾の有無を区別して染色する方法を示す(図1、修飾の有無(リン酸化、糖付加等))。分子によっては活性化に伴ってリン酸化などの修飾を受ける場合がある。また、糖鎖の有無が生体反応に重要な役割をはたしている場合もある。ここでは、リン酸化を受けた分子について説明するが、糖鎖による修飾も同様に検出することができる。
分子によっては、活性化等に伴って、他のタンパク質との相互作用に変化が生じる場合がある。タンパク質Eが単独で存在する場合と、他の分子Xと複合体を形成している場合とを区別して染色する方法について説明する(図1、相互作用(タンパク質等))。
タンパク質は修飾、あるいは複合体形成によって、立体構造自体が大きく変化する場合もある。本実施形態の染色方法で立体構造の変化を捉えることも可能である(図1、立体構造の変化)。
がん細胞では、点突然変異、あるいは欠失変異など複数の変異が同一タンパク質に生じることも多い。本発明の方法は2つの異なる抗体を用いた二重染色だけではなく、3つ以上の変異を区別して染色することも可能である。
以下に本発明の多重染色法を適用した例を実施例として示す。
Claims (5)
- 細胞を含む検体を固定化した標本において、複数の抗体を用いて検出する多重染色法であって、
特定の分子の存在を検出するための抗体と
前記特定の分子の変化を検出するための抗体とを用いることを特徴とする多重染色法。 - 前記特定の分子が治療薬の標的となる細胞抗原タンパク質であって、
当該治療薬の効果を判定するために用いることを特徴とする請求項1記載の多重染色法。 - 細胞を含む検体を固定化した標本において、分子の変化を検出するためのキットであって、
特定の分子の存在を検出する抗体と
前記特定の分子の変化を検出するための少なくとも1つ以上の抗体と、
前記特定の分子の存在を検出する抗体と前記特定の分子の変化を検出するための少なくとも1つ以上の抗体とを、夫々識別可能に標識する標識を含むことを特徴とする多重染色キット。 - 前記特定の分子が治療薬の標的になる細胞抗原タンパク質であって、
当該治療薬の効果を判定するために用いることを特徴とする請求項3記載の多重染色キット。 - 前記特定の分子がPD-L1又はPD-L2であって、
PD-L1又はPD-L2の存在を検出するための抗体と、
PD-L1又はPD-L2のC末領域の変化に伴って認識されない抗体とを含むことを特徴とする請求項3又は4記載の多重染色キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016116346 | 2016-06-10 | ||
JP2016116346 | 2016-06-10 | ||
PCT/JP2017/020927 WO2017213117A1 (ja) | 2016-06-10 | 2017-06-06 | 多重染色法、及び染色キット |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017213117A1 JPWO2017213117A1 (ja) | 2019-04-04 |
JP6781252B2 true JP6781252B2 (ja) | 2020-11-04 |
Family
ID=60578772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018522496A Active JP6781252B2 (ja) | 2016-06-10 | 2017-06-06 | 多重染色法、及び染色キット |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6781252B2 (ja) |
WO (1) | WO2017213117A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050373A1 (ja) * | 2018-09-06 | 2020-03-12 | コニカミノルタ株式会社 | 情報取得方法、情報取得装置及びプログラム |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ751260A (en) * | 2013-03-15 | 2021-07-30 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
US10585100B2 (en) * | 2015-04-30 | 2020-03-10 | Kyoto University | Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index |
-
2017
- 2017-06-06 WO PCT/JP2017/020927 patent/WO2017213117A1/ja active Application Filing
- 2017-06-06 JP JP2018522496A patent/JP6781252B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2017213117A1 (ja) | 2019-04-04 |
WO2017213117A1 (ja) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101716555B1 (ko) | 포유동물 대상체에서 5t4-양성 순환 종양 세포를 검출하는 방법 및 5t4-양성 암을 진단하는 방법 | |
US20130338016A1 (en) | Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis | |
KR20080066663A (ko) | 맞춤화된 항암 화학요법(pac)을 위한 종합적인 진단테스트 방법 | |
US20170336391A1 (en) | Tumor cell isolation/purification process and methods for use thereof | |
Uhr et al. | Molecular profiling of individual tumor cells by hyperspectral microscopic imaging | |
US20150051104A1 (en) | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient | |
CN113366317A (zh) | 用于囊泡货物标记和检测的系统和方法 | |
KR20220100854A (ko) | 인공 지능 기반 세포 분석을 위한 시스템 및 방법 | |
EP1604184A2 (en) | Standardized evaluation of therapeutic efficacy based on cellular biomarkers | |
US20100151447A1 (en) | Method for double staining in immunohistochemistry | |
JP6781252B2 (ja) | 多重染色法、及び染色キット | |
MX2014015656A (es) | Cuantificacion de marcador en celulas individuales en secciones de tejido. | |
JP6675716B2 (ja) | 免疫因子を指標とした肺腺癌の予後演算式作成方法と予後推定方法 | |
JP7525474B2 (ja) | パーキンソン病の判定 | |
Lennerz et al. | Keratin 19 epithelial patterns in cirrhotic stroma parallel hepatocarcinogenesis | |
DK2856166T3 (en) | PROCEDURE FOR DIAGNOSIS OF MAMMALS | |
Linke | Diagnosis of minimal amyloid deposits by congo red fluorescence and amyloid type-specific immunohistochemistry: A review | |
CN115552248A (zh) | 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法 | |
KR20120056660A (ko) | Alk 유전자의 재배열 검출방법 및 이를 이용한 암 진단방법 | |
US20140275292A1 (en) | Systems and methods employing human stem cell markers for detection, diagnosis and treatment of circulating tumor cells | |
CN104849228B (zh) | 使用基于uv 光的dna 成像细胞术来检测和/或诊断癌症的体外方法 | |
KR102546414B1 (ko) | 다중 면역조직화학염색을 이용한 암 환자의 면역 관문 억제제에 대한 치료 반응성을 예측하기 위한 정보를 제공하는 방법 | |
US11447550B2 (en) | Peptides for molecular detection of PD-L1 | |
Diaz et al. | Cerebrospinal fluid circulating tumor cells for diagnosis, response evaluation, and molecular profiling of | |
Saggese | A novel method to quantify gamma H2AX foci in circulating tumour cells in patients receiving chemotherapy for colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200529 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200928 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201015 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6781252 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |